Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | FGF1 | P05230 | 2/20 | 0.33 |
| ▸ | GJB2 | P29033 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13159060 | 0.88 | LGALS3 (0.39) | FGF1THRBLGALS8 | |
| SCHEMBL14586218 | 0.83 | LGALS8 (0.33) | FGF1GJB2LGALS8 | |
| SCHEMBL16442174 | 0.80 | LGALS8 (0.36) | FGF1GJB2LGALS8 | |
| SCHEMBL13160717 | 0.80 | LGALS3 (0.42) | THRBLGALS8 | |
| SCHEMBL17169660 | 0.80 | LGALS3 (0.42) | THRBLGALS8 | |
| SCHEMBL13160719 | 0.79 | LGALS3 (0.39) | THRBLGALS8 | |
| SCHEMBL16442179 | 0.78 | LGALS8 (0.35) | FGF1GJB2LGALS8 | |
| SCHEMBL17169663 | 0.77 | LGALS3 (0.39) | THRBLGALS8 | |
| SCHEMBL17169665 | 0.77 | CD69 (0.38) | LGALS8 | |
| SCHEMBL14586217 | 0.77 | CA2 (0.34) | FGF1LGALS8F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008755-A1 | PHARMACEUTICAL FORMULATION OF CHOLANIC ACID-CHITOSAN COMPLEX INCORPORATED WITH HYDROPHOBIC ANTICANCER DRUGS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008755-A1 | PHARMACEUTICAL FORMULATION OF CHOLANIC ACID-CHITOSAN COMPLEX INCORPORATED WITH HYDROPHOBIC ANTICANCER DRUGS AND PREPARATION METHOD THEREOF | CHIA, LIPA, CHCHD6 | ALOX15 1863/4885FGF1 980/4885GJB2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.